Primary study outcomes stratified by confirmed diagnosis of heparin-induced thrombocytopenia
| . | Argatroban/danaparoid n/N (%) . | Fondaparinux n/N (%) . | P* . |
|---|---|---|---|
| HIT diagnosed during hospitalization | |||
| Primary efficacy outcome† | |||
| Unmatched cohort | 10/38 (26.3) | 7/44 (15.9) | .246 |
| Matched cohort | 5/20 (25.0) | 7/44 (15.9) | .492 |
| Primary safety outcome‡ | |||
| Unmatched cohort | 7/38 (18.4) | 16/44 (36.4) | .071 |
| Matched cohort | 1/20 (5.0) | 16/44 (36.4) | .008 |
| HIT not diagnosed during hospitalization | |||
| Primary efficacy outcome† | |||
| Unmatched cohort | 11/68 (16.2) | 15/89 (16.9) | .910 |
| Matched cohort | 8/40 (20.0) | 15/89 (16.9) | .666 |
| Primary safety outcome‡ | |||
| Unmatched cohort | 20/68 (29.4) | 12/89 (13.5) | .014 |
| Matched cohort | 11/40 (27.5) | 12/89 (13.5) | .054 |
| . | Argatroban/danaparoid n/N (%) . | Fondaparinux n/N (%) . | P* . |
|---|---|---|---|
| HIT diagnosed during hospitalization | |||
| Primary efficacy outcome† | |||
| Unmatched cohort | 10/38 (26.3) | 7/44 (15.9) | .246 |
| Matched cohort | 5/20 (25.0) | 7/44 (15.9) | .492 |
| Primary safety outcome‡ | |||
| Unmatched cohort | 7/38 (18.4) | 16/44 (36.4) | .071 |
| Matched cohort | 1/20 (5.0) | 16/44 (36.4) | .008 |
| HIT not diagnosed during hospitalization | |||
| Primary efficacy outcome† | |||
| Unmatched cohort | 11/68 (16.2) | 15/89 (16.9) | .910 |
| Matched cohort | 8/40 (20.0) | 15/89 (16.9) | .666 |
| Primary safety outcome‡ | |||
| Unmatched cohort | 20/68 (29.4) | 12/89 (13.5) | .014 |
| Matched cohort | 11/40 (27.5) | 12/89 (13.5) | .054 |